Filing Flows › Biodesix (BDSX) › Guidance & outlook
Biodesix (BDSX) guidance and outlook
Biodesix (BDSX) lowered its guidance on Nov 5, 2026: Revenue $101M–$103M for FY2026; Revenue +15% for FY2026; Gross margin 80% for FY2026. Biodesix's 10-Q filed Nov 5, 2026 makes 27 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $101M–$103M | lowered |
| Revenue | FY2026 | +15% | lowered |
| Gross margin | FY2026 | 80% | reaffirmed |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- We envision a world where patient disease is conquered through the guidance of personalized diagnostics.
- We currently offer two tests (Nodify Lung® tests) that assess the risk of cancer in lung nodules and three tests (IQLung® tests) that provide treatment guidance after a lung cancer diagnosis.
- If we are not able to obtain or maintain coverage and adequate reimbursement from third-party payers, we may not be able to effectively increase our testing volume and revenue as expected.
- While we currently expect this trend to continue, there is no guarantee of future reimbursement performance from this particular payer or any other payer.
- On September 24, 2026, the Company announced strategic progress in two collaborative programs for tumor-informed and tumor-naïve MRD solutions intended to support cancer centers and clinical laboratories.
- We also expect to incur research and development expenses to fund further innovation and develop new clinically relevant tests.
- We believe these studies, collaborative arrangements, and the continued development of our product pipeline are critical to gaining physician adoption and driving favorable coverage decisions by payers and expect our investments in research and development to increase.
- We expect to increase our sales and marketing expenses in furtherance of this as we continue to develop these relationships, and we expect to support a growing number of investigations and clinical trials.
- If our relationships expand, we believe we may have opportunities to offer our platform for companion diagnostic development, novel target discovery and validation efforts, and to grow into
- For example, we believe our multi-omic data including genomic and proteomic data, in combination with clinical outcomes or claims data, has revenue-generating potential, including for novel target identification and companion diagnostic discovery and development.
- We plan to continue investing in the field sales force through select expansion and provide them with tools that maximize their education and selling efforts to achieve greater returns.
- Additionally, we plan to invest in the marketing and customer support teams to continue to provide the field sales force with the resources to be successful.
Biodesix's latest quarter
Biodesix, Q3 2026: revenue $24.0M (+10% year over year), operating margin -25.4%, net loss $8.0M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
Questions
Did Biodesix raise or lower its guidance?
Biodesix (BDSX) lowered its guidance on Nov 5, 2026: Revenue $101M–$103M for FY2026; Revenue +15% for FY2026; Gross margin 80% for FY2026.
What does Biodesix expect?
We envision a world where patient disease is conquered through the guidance of personalized diagnostics. We currently offer two tests (Nodify Lung® tests) that assess the risk of cancer in lung nodules and three tests (IQLung® tests) that provide treatment guidance after a lung cancer diagnosis. If we are not able to obtain or maintain coverage and adequate reimbursement from third-party payers, we may not be able to effectively increase our testing volume and revenue as expected.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.